Trial Profile
A phase 2a, randomized, double-blind, placebo-controlled,dose-escalation study to evaluate the safety and tolerability of multiple-dose subcutaneous administration of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody,when administered to adults with mild persistent asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Enokizumab (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors MedImmune
- 29 Oct 2008 Results were presented at CHEST 2008.
- 05 Oct 2008 Status changed from suspended to completed, based on information from ClinicalTrials.gov.
- 25 Aug 2008 Status changed from active, no longer recruiting to suspended, based on information from ClinicalTrials.gov.